Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dextrose
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aphaia's Lead Drug Shows Positive Phase 2 Results for Prediabetes
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently in mid-stage trial for treating patients with type-2 prediabeteic condition.
Brand Name : APHD-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently undergoing mid-stage clinical trials for treating patients with obesity.
Brand Name : APHD-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 13, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aphaia Provides Enrollment and Protocol Update for Phase 2 Trial in Obesity Patients
Details : Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently undergoing mid-stage clinical trials for treating patients with obesity.
Brand Name : APHD-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2024
Lead Product(s) : Dextrose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Glucose
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : APH-012 (dextrose) is a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated for chronic weight management in patients with obesity and to improve glucose tolerance in patient...
Brand Name : APH-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2023
Lead Product(s) : Glucose
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : APH-012 is a glucose formulation designed to be released at discrete parts of the small intestine to restore endogenous nutrient-sensing signaling pathways and stimulate the release of the broad spectrum of enteric hormones that control multiple homeosta...
Brand Name : APH-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2022
Lead Product(s) : Glucose
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?